Foundation Medicine Announces Positive Data from CUPISCO Study in Difficult to Treat CUP Patients Will be Presented at ESMO
Foundation Medicine and Roche announced the a late breaking abstract on their precision oncology study, CUPISCO, which aimed to assess the effectiveness of molecularly guided therapy for patients with unfavorable subset cancer of unknown primary (CUP) will be presented at the European Society of Medical Oncology (ESMO) meeting which starts on October 20, 2024. Patients with CUP present a challenge because the origin of the tumor is unknown, making targeted treatment difficult. Historically, this lack of knowledge has led to poor outcomes for these patients. The study revealed that genomic profiling, utilizing Foundation Medicine’s FDA-approved FoundationOne®CDx and FoundationOne®Liquid CDx diagnostic tests, had a positive impact on both progression-free survival and overall survival in patients with CUP. This is an important step toward improving the prognosis and treatment options for these individuals.
The CUPISCO study compared the efficacy of targeted therapy or immunotherapy guided by comprehensive genomic profiling when compared to standard platinum based chemotherapy in patients with CUP. 85% of CUP cases have clinically relevant genomic alterations. According to data from the Minnie Pearl Cancer Research Network, CUP patients have a median survival of only 9.1 months, one year survival of only 38%, and five year survival of only 10%.
The study planned to recruit 79 patients with CUP into two arms with one using comprehensive genomic profiling using Foundation Medicine’s test to determine treatment. Primary endpoints were overall survival, overall response rate, duration of clinical benefit, and adverse events.
The fact that overall survival and progression free survival improved in this difficult-to-treat patient population using comprehensive genomic profiling could lead to greater clinical adoption and reimbursement coverage for this patient population.